

TG THERAPEUTICS, INC.  
Form 8-K  
December 17, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **December 15, 2014**

**TG Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**

**001-32639**

**36-3898269**

(State or Other Jurisdiction (Commission File Number)

(IRS Employer Identification No.)

of Incorporation)

**3 Columbus Circle, 15<sup>th</sup> Floor**

**New York, New York 10019**

(Address of Principal Executive Offices)

**(212) 554-4484**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 15, 2014, the Board of Directors (the “Board”) of the TG Therapeutics, Inc. (the “Company”) appointed Kenneth Hoberman to the Board. Mr. Hoberman will serve as a director until his term expires at the 2015 annual meeting of stockholders, at which time he will stand for election by the Company’s stockholders. Mr. Hoberman will serve as a member of the Company’s Compensation Committee. The Board announced Mr. Hoberman’s appointment via press release on December 17, 2014. A copy of the press release is being filed as Exhibit 99.1 and incorporated in this Item by reference.

**Item 9.01 Financial Statements And Exhibits.**

(d) Exhibits.

99.1 Press Release of TG Therapeutics, Inc., dated December 17, 2014.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**TG Therapeutics, Inc.**  
(Registrant)

Date: December 17, 2014 By: /s/ Sean A. Power  
Sean A. Power  
Chief Financial Officer

**INDEX TO EXHIBITS**

**Exhibit**  
**Number** **Description**

99.1 Press Release of TG Therapeutics, Inc., dated December 17, 2014.